-
Sector Analysis
NewOvarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Ovarian Cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases. Ovarian Cancer is one of the most lethal gynecological cancers worldwide. Despite being...
-
Sector Analysis
Head and Neck Squamous Cell Carcinomas (HNSCC) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
The Head and Neck Squamous Cell Carcinomas (HNSCC) market size for the 15 markets (15M) was $1.9 billion in 2021. HNSCC have an active cell therapy pipeline and one of the largest gene therapy/oncolytic virus clinical pipelines across all oncology indications. HNSCCs are characteristically aggressive tumors, disseminating relatively early, as observed in the high rates of metastatic disease at diagnosis. Late-stage cases constitute around 60% of all HNSCC cases. The growth of the primary tumor is associated with the presence...
-
Sector Analysis
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Glioblastoma Multiforme Market Report Overview The Glioblastoma Multiforme market value for the 15 markets (15M) was $630 million in 2021. This included both CGTs and established/traditional GBM therapies. The Glioblastoma Multiforme market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by the market for...
-
Sector Analysis
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Chronic Lymphocytic Leukemia (CLL) Market Report Overview The Chronic Lymphocytic Leukemia (CLL) market value for the 15 markets (15M) was $13.2 billion in 2021. This included both cell therapies and established/traditional CLL therapies. The 15 markets comprise the 8 major markets and seven countries known to have increased potential for cell therapies given the current drug development landscape, namely Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada. The CLL market research report provides an analysis of the key dynamics...
-
Sector Analysis
Multiple Myeloma – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Explore in-depth market insights from the following data in our ‘Multiple Myeloma Cell Therapy Market’ report: Access updated epidemiology for patient populations relevant to cell therapy in 2021-2031 Review updated prescription habits at the class level for already established therapies (defined in our analysis as chemotherapy, targeted therapies, and others [such as immune checkpoint inhibitors or hormone therapies]) and compare their future projections to cell therapy pipeline drugs Full market assessment in the 8MM of all currently marketed and late-stage pipeline cell therapy drugs with drug-level forecasts, supplemented by class-level forecasts for early-stage molecules Explore indication-specific top-line sales forecasts across 15 countries, in the 8MM and...
-
Sector Analysis
Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Accessing in-depth insights from the ‘Acute Lymphocytic Leukemia Cell Therapy Market’ report will help you: Assess the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) and identify the potential countries for growth opportunities within the ALL-cell therapy market. Analyze the clinical and commercial landscapes of each indication, with pricing assumptions Evaluate indication-specific unmet needs and competitive assessments by Class of Therapy Identify the Likelihood of Approval Analysis...
-
Sector Analysis
Colorectal Cancer Cell and Gene Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Colorectal Cancer Market Report Overview The Colorectal Cancer (CRC) 15 (CGT and established/conventional therapies) market size was $18.9 billion in 2021. CRC has one of the largest gene therapy/oncolytic virus clinical pipelines across all of oncology, and a relatively active clinical cell therapy pipeline compared to other solid tumors. There are currently no marketed or Phase III CGT agents in CRC, reflecting the difficulties of progressing these drug types into the CRC market. This is largely due to insufficient efficacy; however, there...
-
Sector Analysis
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031
Access and explore the following in-depth insights from the ‘B-Cell Non-Hodgkins Lymphoma Cell Therapy Market’ report: Disease epidemiology including - Patient segmentation, staging & progression rates, and Disease incidence/prevalence. Marketed products with a breakdown established versus cell therapies, backed with primary research validated base year forecast Commercial assessment and Forecast by number of patients treated per class and future sales projection based on competitive assessment Launch date assessment with estimated launch dates by class of cell therapy and indication-specific assumptions. Evaluation...
-
Thematic Analysis
Impact of Brazil on the Pharmaceutical Industry – Thematic Intelligence
Brazil Pharmaceutical Market Report Overview Brazil is the largest pharmaceutical market in Central/Southern America and is the 12th largest in the world. Brazil is an untapped market for big pharma manufacturing, with domestic companies dominating the marketed products landscape. The domestic pharmaceutical companies will continue to grow due to favorable policies provided by the Brazilian government to promote domestic production of medicines. Furthermore, over the years, Brazil has elevated its infrastructure, scientific, and technological facilities and has created a sustainable...
-
Sector Analysis
Acute Myeloid Leukemia Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Acute Myeloid Leukemia Market Report Overview The AML market value for the 15 markets (15M) was $3.1 billion in 2021. Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by the abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. The first approval for cell therapy drugs is anticipated in 2023, which is expected to positively...